Based on observations that IL-1β and IL-18 can contribute to AML anti-cancer drug resistance, and based on our data showing enhanced expression of PELI2 gene, mediating IL-1β and IL-18 activation may be a distinct plausible important mechanism by which PELI2 involved in emergence of drug resistance42–45. This evidence concerns the gene IL1B and acute myeloid leukemia.